BUFFALO, N.Y., June 1, 2015 /PRNewswire/ -- Albany
Molecular Research Inc. (NASDAQ: AMRI) announced today that it has
signed a collaborative agreement with biotechnology company
HarkerBIO LLC to co-market their structure-based drug discovery
services to global pharmaceutical and biotechnology clients. As
part of the three-year agreement, AMRI gains access to HarkerBIO's
uniquely differentiated high-resolution, structure-determination
expertise and capabilities. HarkerBIO's customers will be able to
access and benefit from AMRI's global capabilities, including their
integrated drug discovery platforms and solutions.
"We are excited to be entering into this collaboration with
HarkerBIO as we implement our new drug-discovery site in
Buffalo, N.Y. Our new center in
Buffalo offers customers
leading-edge platforms and capabilities to translate early
discoveries to the clinic via an integrated approach leveraging our
expertise in chemistry, biology and pharmacology all located in a
single site in the United States,"
said Michael A. Luther, Senior Vice
President, Discovery and Development, AMRI.
Aimed at accelerating decision making and success in the
translation from discovery to the clinic, the alliance with
HarkerBIO is an early example of the types of partnerships AMRI is
creating. AMRI's new discovery center is co-located on the Buffalo
Niagara Medical Campus and is part of the larger commitment by the
State of New York.
"We have a responsibility to our partners and customers to help
drive the translation of innovation to the clinic to bridge the
current gaps in discovery and development," Dr. Luther said, "Our
strategy is to leverage and build creative and effective
collaborations with on-campus and off-campus partners from global
Pharma to academia including technology partners within this unique
public-private environment."
"We are thrilled to be entering this collaborative agreement
with AMRI, one of the most well-respected global drug discovery
solution providers," says Paul
Sargeant, CEO of HarkerBIO. "We are excited to bring
HarkerBIO's unique structural biology services to AMRI's
customers."
Financial terms of the agreement were not disclosed.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API) and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids and cytotoxic compounds.
Drug Product Manufacturing supports drug product development
through commercial scale production of complex liquid-filled and
lyophilized parenteral formulations. For more information about
AMRI, please visit our website at www.amriglobal.com or follow us
on Twitter (@amriglobal).
About The Buffalo Medical Innovation and Commercialization
Hub
The Buffalo Medical Innovation and Commercialization
Hub (the "BMIC Hub") at the Buffalo Niagara Medical Campus is part
of a 10-year, $1 billion
public-private research and development initiative announced by
New York Governor Andrew M. Cuomo in December 2012. Albany Molecular Research Inc.
(AMRI), a recognized leader in drug discovery, development and
manufacturing services, is a partner in this initiative.
About HarkerBIO LLC
HarkerBIO is a biotechnology
company that provides services to rapidly and cost effectively
advance the development of pharmaceuticals. Based on
technologies developed at the world-renowned Hauptman-Woodward
Medical Research Institute (HWI), HarkerBIO determines the near
atomic-resolution, three-dimensional structures of drug target and
drug target - therapeutic agent complexes, to greatly accelerate
the drug design process. HarkerBIO's technology directly images a
drug's mechanism of action, which is critical to optimize a drug
candidate and to capture a strong IP position. Through our
high-throughput pipeline, pharmaceutical and biotechnology
companies gain access to the latest and most advanced technologies
in Structural Biology. Specifically, HarkerBIO provides a
state-of-art pipeline from protein expression and purification,
target crystallization, structure determination, through to drug
discovery. Through partnerships with industry, we are developing
the next generation of therapeutics for a broad spectrum of
diseases and health conditions.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-and-harkerbio-ink-collaborative-agreement-in-buffalo-ny-300091165.html
SOURCE AMRI